Search results for " ARTERIAL HYPERTENSION"

showing 9 items of 29 documents

Relationship between plasma endothelin-1 and aortic stiffness in hypertensive patients with chronic kidney disease

2012

Plasma endothelin aortic stiffnes chronic kidney disease arterial hypertension
researchProduct

Mild obstructive sleep apnea increases hypertension risk, challenging traditional severity classification

2020

STUDY OBJECTIVES: The association of mild obstructive sleep apnea (OSA) with important clinical outcomes remains unclear. We aimed to investigate the association between mild OSA and systemic arterial hypertension (SAH) in the European Sleep Apnea Database cohort. METHODS: In a multicenter sample of 4,732 participants, we analyzed the risk of mild OSA (subclassified into 2 groups: mild(AHI 5-<11/h) (apnea-hypopnea index [AHI], 5 to <11 events/h) and mild(AHI 11-<15/h) (AHI, ≥11 to <15 events/h) compared with nonapneic snorers for prevalent SAH after adjustment for relevant confounding factors including sex, age, smoking, obesity, daytime sleepiness, dyslipidemia, chronic obstructive pulmona…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyEuropean Sleep Apnea Database Mild obstructive sleep apnea Systemic arterial hypertensionPolysomnographyDisorders of Excessive SomnolenceSettore MED/10 - Malattie Dell'Apparato RespiratorioHypertension risk03 medical and health sciences0302 clinical medicinestomatognathic systemRisk FactorsInternal medicinesystemic arterial hypertensionmedicineHumansEuropean Sleep Apnea DatabaseSleep Apnea ObstructiveSystemic arterial hypertensionbusiness.industrymedicine.diseaseScientific InvestigationsClinical neurologyrespiratory tract diseasesnervous system diseasesObstructive sleep apneamild obstructive sleep apneaDiabetes Mellitus Type 2NeurologyHypertensionNeurology (clinical)Human medicinebusiness030217 neurology & neurosurgery
researchProduct

Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry

2021

OBJECTIVE: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice. METHODS: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping ri…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyRegistryMedDRAPeripheral edemaClinical practicePulmonary arterial hypertensionRiociguatlaw.inventionPulmonary hypertension03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicine030212 general & internal medicineAdverse effectHipertensió pulmonarRiociguatbusiness.industrymedicine.diseasePulmonary hypertensionClinical trial030228 respiratory systemPulmonary hemorrhagemedicine.symptomSafetybusinessmedicine.drug
researchProduct

ASSOCIATION OF RENAL RESISTIVE INDEX WITH CAROTID INTIMA-MEDIA THICKNESS IN HYPERTENSIVE PATIENTS

2014

RENAL RESISITVE INDEX AORTIC STIFFNESS PULSE WAVE VELOCITY RENAL FUNCTION ARTERIAL HYPERTENSION
researchProduct

Pulmonary hypertension in pediatrics. a feasible approach to bridge the gap between real world and guidelines

2019

Pulmonary hypertension (PH) is quite infrequent in pediatric age and its most common etiologies include idiopathic pulmonary arterial hypertension, PH related to congenital heart diseases, bronchopulmonary dysplasia (chronic lung disease), persistence of pulmonary hypertension of the newborn, and congenital diaphragmatic hernia. The developed for adult patients PH classification shows limitations when applied to pediatric subjects since the underlying causes are markedly different between the two ages. In 2011, the Pulmonary Vascular Research Institute Panama Task Force outlined the first specific pediatric pulmonary hypertensive vascular disease diagnostic classification, including 10 main…

Right heart catheterizationAdultHeart Defects CongenitalPediatricsmedicine.medical_specialtynewbornsHypertension Pulmonary030204 cardiovascular system & hematologyBridge (interpersonal)Pediatrics03 medical and health sciences0302 clinical medicinechildrenpulmonary arterial hypertensionpulmonary hypertensionmedicineHumansright heart catheterizationChildBronchopulmonary Dysplasiabusiness.industrychildren; congenital heart disease; newborns; pulmonary arterial hypertension; pulmonary hypertension; right heart catheterizationIdiopathic Pulmonary Arterial HypertensionInfant NewbornObstetrics and GynecologyPediatric agemedicine.diseasePulmonary hypertensioncongenital heart disease030228 respiratory systemPediatrics Perinatology and Child HealthEtiologybusinessHernias Diaphragmatic Congenital
researchProduct

[OP.2D.05] RELATIONSHIP OF OXIDATIVE STRESS WITH CARDIAC HYPERTROPHY IN HYPERTENSIVE PATIENTS

2016

OBJECTIVE: Left ventricular hypertrophy is common in hypertensive patients. In these subjects increased oxidative stress has been observed. Our aim was to evaluate the association of biomarkers of both oxidative stress and inflammation with markers of cardiovascular damage in a large group of hypertensives with different stages of renal function. DESIGN AND METHOD: In 517 hypertensives we analyzed left ventricular mass indexed for body surface area, and we assayed plasma levels of 8-isoprostaglandin F2alpha and high sensitivity C reactive protein. RESULTS: Multivariate analysis carried out considering left ventricular mass as dependent variable, and including 8-isoprostaglandin F2alpha, hig…

Settore MED/14 - Nefrologiamedicine.medical_specialtySettore MED/09 - Medicina InternaPhysiologybusiness.industrymedicine.disease_causeLEFT VENTRICULAR HYPERTROPHY - ARTERIAL HYPERTENSION - OXIDATIVE STRESSSettore MED/11 - Malattie Dell'Apparato CardiovascolareCardiac hypertrophyInternal medicineInternal MedicinemedicineCardiologyCardiology and Cardiovascular MedicinebusinessOxidative stressJournal of Hypertension
researchProduct

[OP.7B.08] INFLUENCE OF GENDER ON THE RELATIONSHIPS BETWEEN NEW INDICES OF ADIPOSITY AND LEFT VENTRICULAR MASS AND HYPERTROPHY IN HYPERTENSIVE PATIEN…

2016

OBJECTIVE: The unfavourable effects of the association of obesity with hypertension on cardiac structure and function have been extensively studied. However, controversy still exists about the influence of gender on the relationship between obesity and left ventricular mass (LVM) and hypertrophy (LVH). Even if body mass index (BMI) and waist circumference (WC) are widely used as anthropometric predictors for cardiovascular diseases (CVD), their validity has been questioned. Recently, Body Shape Index (ABSI) and Body Roundness Index (BRI) were proposed as alternative measures of adiposity that may better reflect health status (1-2).Our study was aimed to assess the ability of ABSI and BRI in…

medicine.medical_specialtySettore MED/09 - Medicina InternaPhysiologybusiness.industrySettore MED/11 - Malattie Dell'Apparato CardiovascolareMuscle hypertrophyLeft ventricular massEndocrinologyInternal medicineobesity - arterial hypertension - left ventricular hypertrophyInternal MedicinemedicineCardiologyCardiology and Cardiovascular Medicinebusiness
researchProduct

Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension

2020

Abstract Background Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis (SSc), associated with a progressive elevation in pulmonary vascular resistance and subsequent right heart failure and death. Due to unspecific symptoms, the diagnosis of PAH is often delayed. On this basis, it is of great value to improve current diagnostic methods and develop new strategies for evaluating patients with suspected PAH. Interleukin-32 (IL-32) is a proinflammatory cytokine expressed in damaged vascular cells, and the present study aimed to assess if this cytokine could be a new biomarker of PAH during SSc. Methods The IL-32 expression was evaluated in the sera and skin sam…

medicine.medical_specialtylcsh:Diseases of the musculoskeletal systemHypertension Pulmonarymedicine.medical_treatment030204 cardiovascular system & hematologyPulmonary arterial hypertensionGastroenterologyProinflammatory cytokineSystemic sclerosi03 medical and health sciences0302 clinical medicineInternal medicinemedicine.arterysystemic sclerosis; pulmonary arterial hypertension; IL-32medicineHumansskin and connective tissue diseases030203 arthritis & rheumatologyScleroderma Systemicintegumentary systembusiness.industryInterleukinsRheumatologyInterleukin 32Cytokinemedicine.anatomical_structureIL-32; Pulmonary arterial hypertension; Systemic sclerosisIL-32Pulmonary arteryVascular resistanceSystemic sclerosisBiomarker (medicine)Immunohistochemistrylcsh:RC925-935businessBiomarkersResearch ArticleArthritis Research &amp; Therapy
researchProduct

Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document

2009

Abbreviations ACE: angiotensin-converting enzyme; BP: blood pressure; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; ESC: European Society of Cardiology; ESH: European Society of Hypertension; ET: endothelin; IMT: carotid intima-media thickness; JNC: Joint National Commit

medicine.medical_specialtymanagement arterial hypertensionPhysiologyupdateRenal functionBlood PressureInternal medicinemedicineInternal MedicineHumanscardiovascular diseasesAntihypertensive AgentsTask forcebusiness.industryHypertension GuidelineHypertension managementGeneral MedicineEuropeOrgan damageBlood pressureHypertensionPractice Guidelines as Topiccardiovascular systemCardiologyMED/09 - MEDICINA INTERNAbusinessEndothelin receptorCardiology and Cardiovascular Medicine
researchProduct